{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T01:08:58Z","timestamp":1793581738242,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1093\/annonc\/mdz176","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T07:11:57Z","timestamp":1559027517000},"page":"1370-1380","source":"Crossref","is-referenced-by-count":278,"title":["Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-3080","authenticated-orcid":false,"given":"L.","family":"Khoja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.","family":"Atenafu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Suciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Leyvraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Piulats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.T.","family":"Kivel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pfoehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Huppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.B.J.","family":"Van Iersel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.J.M.","family":"De Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Penel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fiorentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mouriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1093\/annonc\/mdz176_bb0010","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1093\/annonc\/mdz176_bb0015","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1093\/annonc\/mdz176_bb0020","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1200\/JCO.2004.08.194","article-title":"Screening for metastasis from choroidal melanoma: the collaborative ocular melanoma study group report 23","volume":"22","author":"Diener-West","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz176_bb0025","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archopht.119.5.670","article-title":"Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (COMS): COMS report no. 15","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1093\/annonc\/mdz176_bb0030","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/eye.2012.255","article-title":"Molecular pathology of uveal melanoma","volume":"27","author":"Coupland","year":"2013","journal-title":"Eye (Lond)"},{"issue":"8","key":"10.1093\/annonc\/mdz176_bb0035","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1093\/annonc\/mdz176_bb0040","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1093\/annonc\/mdz176_bb0045","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat Genet"},{"issue":"6009","key":"10.1093\/annonc\/mdz176_bb0050","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"issue":"6","key":"10.1093\/annonc\/mdz176_bb0055","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ng.3549","article-title":"Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma","volume":"48","author":"Moore","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"10.1093\/annonc\/mdz176_bb0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","article-title":"Effectiveness of treatments for metastatic uveal melanoma","volume":"148","author":"Augsburger","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"23","key":"10.1093\/annonc\/mdz176_bb0065","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial","volume":"311","author":"Carvajal","year":"2014","journal-title":"JAMA"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdz176_bb0070","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdz176_bb0075","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz176_bb0080","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cam4.133","article-title":"Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives","volume":"2","author":"Buder","year":"2013","journal-title":"Cancer Med"},{"key":"10.1093\/annonc\/mdz176_bb0085","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no","volume":"123","author":"Diener-West","year":"2005","journal-title":"26. Arch Ophthalmol"},{"issue":"6","key":"10.1093\/annonc\/mdz176_bb0090","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jso.23535","article-title":"The Liverpool uveal melanoma liver metastases pathway: outcome following liver resection","volume":"109","author":"Gomez","year":"2014","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz176_bb0095","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz176_bb0100","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mdz176_bb0105","series-title":"AJCC Cancer Staging Manual","author":"Edge","year":"2009"},{"issue":"6","key":"10.1093\/annonc\/mdz176_bb0110","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A'Hern","year":"2001","journal-title":"Stat Med"},{"key":"10.1093\/annonc\/mdz176_bb0115","series-title":"Sample Size Calculations in Clinical Research","author":"Chow","year":"2008"},{"key":"10.1093\/annonc\/mdz176_bb0120","series-title":"Statistical Methods for Rates and Proportions","author":"Fleiss","year":"2003"},{"key":"10.1093\/annonc\/mdz176_bb0125","series-title":"Biostatistical Methods","author":"Lachin","year":"2000"},{"key":"10.1093\/annonc\/mdz176_bb0130","series-title":"Sample Size Tables for Clinical Studies","author":"Machin","year":"1997"},{"key":"10.1093\/annonc\/mdz176_bb0135","series-title":"Sample Size Determination and Power.","author":"Ryan","year":"2013"},{"issue":"5","key":"10.1093\/annonc\/mdz176_bb0140","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ajo.2014.07.014","article-title":"Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients","volume":"158","author":"Bol","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1093\/annonc\/mdz176_bb0145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","article-title":"A phase 2 study of tremelimumab in patients with advanced uveal melanoma","volume":"25","author":"Joshua","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdz176_bb0150","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1200\/jco.2014.32.15_suppl.9033","article-title":"Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): the GEM-1 trial","volume":"32","author":"Piulats Rodriguez","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz176_bb0155","doi-asserted-by":"crossref","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdz176_bb0160","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0959-8049(03)00132-1","article-title":"Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma","volume":"39","author":"Kivela","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdz176_bb0165","first-page":"8523.","article-title":"A cancer research UK two-stage multicenter phase II study of imatinib in the treatment of patients with c-kit positive metastatic uveal melanoma (ITEM","volume":"30","author":"Nathan","year":"2012","journal-title":"ASCO Meeting Abstr"},{"issue":"6","key":"10.1093\/annonc\/mdz176_bb0170","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/CMR.0b013e328358b373","article-title":"A pilot study of sunitinib malate in patients with metastatic uveal melanoma","volume":"22","author":"Mahipal","year":"2012","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1093\/annonc\/mdz176_bb0175","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10637-008-9143-2","article-title":"O-Mel-Inib: a Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma","volume":"26","author":"Penel","year":"2008","journal-title":"Invest New Drugs"},{"issue":"11","key":"10.1093\/annonc\/mdz176_bb0180","doi-asserted-by":"crossref","first-page":"e48787","DOI":"10.1371\/journal.pone.0048787","article-title":"Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512","volume":"7","author":"Bhatia","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1093\/annonc\/mdz176_bb0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bjc.2016.119","article-title":"Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study","volume":"115","author":"Mouriaux","year":"2016","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1093\/annonc\/mdz176_bb0190","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1158\/1078-0432.CCR-11-1463","article-title":"Aflibercept (VEGF trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin","volume":"17","author":"Tarhini","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1093\/annonc\/mdz176_bb0195","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1634\/theoncologist.2015-0501","article-title":"Phase II trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic uveal melanoma","volume":"21","author":"Piperno-Neumann","year":"2016","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdz176_bb0200","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00001813-200306000-00002","article-title":"Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study","volume":"14","author":"Pfohler","year":"2003","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1093\/annonc\/mdz176_bb0205","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz176_bb0210","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00008390-200306000-00013","article-title":"Phase II evaluation of temozolomide in metastatic choroidal melanoma","volume":"13","author":"Bedikian","year":"2003","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1093\/annonc\/mdz176_bb0215","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/CMR.0b013e3283403ce9","article-title":"Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma","volume":"20","author":"Homsi","year":"2010","journal-title":"Melanoma Res"},{"issue":"14","key":"10.1093\/annonc\/mdz176_bb0220","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.ejca.2004.04.031","article-title":"A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours","volume":"40","author":"Keilholz","year":"2004","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1093\/annonc\/mdz176_bb0225","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/annonc\/mdl309","article-title":"A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma","volume":"17","author":"Schmittel","year":"2006","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz176_bb0230","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00008390-200510000-00014","article-title":"A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma","volume":"15","author":"Schmittel","year":"2005","journal-title":"Melanoma Res"},{"issue":"33","key":"10.1093\/annonc\/mdz176_bb0235","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1200\/JCO.2008.16.0705","article-title":"Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor","volume":"26","author":"Sato","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz176_bb0240","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1245\/s10434-008-9881-6","article-title":"Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases","volume":"15","author":"van Iersel","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz176_bb0245","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.ejrad.2009.03.064","article-title":"Transarterial chemoembolization of liver metastases in patients with uveal melanoma","volume":"74","author":"Huppert","year":"2010","journal-title":"Eur J Radiol"},{"issue":"4","key":"10.1093\/annonc\/mdz176_bb0250","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00008390-200508000-00011","article-title":"Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study","volume":"15","author":"Patel","year":"2005","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1093\/annonc\/mdz176_bb0255","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jvir.2014.11.037","article-title":"Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases","volume":"26","author":"Valsecchi","year":"2015","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"10.1093\/annonc\/mdz176_bb0260","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00432-006-0155-z","article-title":"Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival","volume":"133","author":"Vogl","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdz176_bb0265","first-page":"131","article-title":"Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study","volume":"23","author":"Fiorentini","year":"2009","journal-title":"In Vivo"},{"issue":"4","key":"10.1093\/annonc\/mdz176_bb0270","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.2007.14.3156","article-title":"Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients","volume":"26","author":"Gimotty","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz176_bb0275","doi-asserted-by":"crossref","first-page":"e0120181","DOI":"10.1371\/journal.pone.0120181","article-title":"Development and external validation of a prognostic nomogram for metastatic uveal melanoma","volume":"10","author":"Valpione","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1093\/annonc\/mdz176_bb0280","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cncr.11113","article-title":"A prognostic model and staging for metastatic uveal melanoma","volume":"97","author":"Eskelin","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdz176_bb0285","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajo.2016.06.002","article-title":"Validation of a prognostic staging for metastatic uveal melanoma: a collaborative study of the European Ophthalmic Oncology Group","volume":"168","author":"Kivela","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"31","key":"10.1093\/annonc\/mdz176_bb0290","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1200\/JCO.2005.02.6534","article-title":"Variates of survival in metastatic uveal melanoma","volume":"23","author":"Rietschel","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419312906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419312906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz176\/28953735\/mdz176.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/8\/1370\/29103586\/mdz176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T05:03:38Z","timestamp":1624683818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419312906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0923753419312906"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz176","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}